Back to Research Home
RMDResMed Inc
Health Care · Health Care Equipment · Large
$252.86−0.08%
As of 23 Oct 2026Mkt cap $33.3B
Stage 13
WAIT
Fundamentals
57.5/75
Technical
8.4/15
Independent
65.9/90
GCAE viewelevated earnings event risk blocks an independent BUY decision
Price
- 1M
- +14.0%
- 3M
- +24.5%
- 6M
- +15.0%
- 1Y
- −5.1%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 24.2xHist median 27.2x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 22.4x
- FCF yield
- 4.5%
Quality
- ROIC
- 27.4%
- Operating margin
- 32.7%
- FCF margin
- 29.2%
- Current ratio
- 3.1x
Growth
- Revenue growth
- +9.9%Latest FY YoY
- Revenue CAGR
- +12.1%
- EPS CAGR
- +18.4%
- FCF CAGR
- +66.2%
Capital
- Share-count trend
- −0.5%3Y annualised
- Net cash
- $1.1B-0.6x OCF
Annual trend
- CAGR 2022–2026
- +12.1%
- Latest · 2026
- $6B
- YoY
- +9.9%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- QUALITY OPPORTUNITY — WAIT FOR SETUP / REPAIR
Key takeaway
Durable compounding, clean cash generation and a more reasonable valuation.
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-10-29
- Stage 13 timing must become entry-permitting on fresh aligned evidence.
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded